华盛顿

我们是谁

  • 1 月 5, 2024
    Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
  • 1 月 5, 2024
    Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
  • 10 月 31, 2023
    表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞(FH-A11KRASG12V-TCR)用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者
  • 2 月 7, 2023
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
  • 12 月 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • 12 月 1, 2022
    Phase 2 Study of DKN-01 in Colorectal Cancer
  • 11 月 15, 2022
    Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
  • 4 月 5, 2022
    CPI-0209 对晚期实体瘤和淋巴瘤患者的研究
  • 4 月 5, 2022
    A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
  • 4 月 5, 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)